Alpha7beta1 Integrin Modulators for Muscle Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for muscular dystrophies such as Duchenne muscular dystrophy, Fukuyama congenital muscular dystrophy, and merosin deficient congenital muscular dystrophy type 1A lack effective solutions for improving muscle regeneration, repair, and maintenance, and there is no cure for these debilitating neuromuscular disorders.
Innovation Solution
Administration of α7β1 integrin modulatory agents like ciclopirox ethanolamine, deferoxamine, 2,2-dipyridyl, and specific compounds (e.g., Compound ID #1001, #1002, #1003) to increase α7β1 integrin expression or activity, enhancing muscle regeneration, repair, or maintenance, and potentially treating muscular dystrophy by improving muscle function and reducing damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for muscular dystrophy, then current standard of care is maintained, but muscle regeneration and repair remain ineffective
Solution Approach 1:
The patent changes the biochemical parameters of muscle cells by introducing compounds that modulate α7β1 integrin expression and activity. This parameter change triggers a shift from ineffective conventional treatment to enhanced muscle regeneration and repair processes, directly addressing the contradiction between maintaining current care standards and achieving effective treatment.
2Productivity
If α7β1 integrin modulatory agents are administered, then muscle regeneration and repair are enhanced, but disease progression may still continue
Solution Approach 1:
The patent applies preliminary action by enhancing muscle regeneration and repair processes before the disease can cause extensive damage. By modulating α7β1 integrin expression in advance, the treatment prepares muscle tissue to better resist and recover from disease progression, addressing the contradiction between accelerating regeneration and preventing long-term disease effects.
3Ease of operation
If no effective treatment is available, then current medical options are limited, but patient quality of life and life span are severely affected
Solution Approach 1:
The patent introduces α7β1 integrin modulatory agents as intermediaries between the existing limited treatment options and the desired outcome of improved patient quality of life. These compounds mediate the interaction between conventional care and enhanced muscle regeneration, providing a bridge that addresses both the scarcity of treatment options and the severe impact on patient outcomes.
Data Source
AI summary
Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.